Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Clinical trial NCT05585034 · COMPLETED

Trial details

NCT number: NCT05585034
Sponsor: Xencor, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma Melanoma Excluding Uveal Melanoma Non-small Cell Lung Cancer, Squamous or Non-squamous Urothelial Carcinoma Renal Cell Carcinoma, Clear Cell Castration-resistant Prostate Cancer Ovarian Cancer, Epithelial TNBC - Triple-Negative Breast Cancer Colorectal Cancer

Start date: 2022-12-14
Primary completion: 2025-05-20
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.